Literature DB >> 32019779

γδ T-cell Receptors Derived from Breast Cancer-Infiltrating T Lymphocytes Mediate Antitumor Reactivity.

Anke Janssen1, Jose Villacorta Hidalgo2,3,4, Dennis X Beringer1, Paul Fisch2,4, Jürgen Kuball5,6, Sanne van Dooremalen1, Febilla Fernando1, Eline van Diest1, Antonela R Terrizi2,4, Peter Bronsert2,4,7,8, Sylvia Kock2,4, Annette Schmitt-Gräff2,4, Martin Werner2,4,7,8, Kerstin Heise9, Marie Follo4,10, Trudy Straetemans1, Zsolt Sebestyen1, Dmitry M Chudakov11,12,13, Sofya A Kasatskaya12,13, Felix E Frenkel14, Sarina Ravens15, Eric Spierings1, Immo Prinz15, Ralf Küppers9, Miroslav Malkovsky16.   

Abstract

γδ T cells in human solid tumors remain poorly defined. Here, we describe molecular and functional analyses of T-cell receptors (TCR) from tumor-infiltrating γδ T lymphocytes (γδ TIL) that were in direct contact with tumor cells in breast cancer lesions from archival material. We observed that the majority of γδ TILs harbored a proinflammatory phenotype and only a minority associated with the expression of IL17. We characterized TCRγ or TCRδ chains of γδ TILs and observed a higher proportion of Vδ2+ T cells compared with other tumor types. By reconstructing matched Vδ2- TCRγ and TCRδ pairs derived from single-cell sequencing, our data suggest that γδ TILs could be active against breast cancer and other tumor types. The reactivity pattern against tumor cells depended on both the TCRγ and TCRδ chains and was independent of additional costimulation through other innate immune receptors. We conclude that γδ TILs can mediate tumor reactivity through their individual γδ TCR pairs and that engineered T cells expressing TCRγ and δ chains derived from γδ TILs display potent antitumor reactivity against different cancer cell types and, thus, may be a valuable tool for engineering immune cells for adoptive cell therapies. ©2020 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32019779     DOI: 10.1158/2326-6066.CIR-19-0513

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  17 in total

Review 1.  Immunotherapy and immunoengineering for breast cancer; a comprehensive insight into CAR-T cell therapy advancements, challenges and prospects.

Authors:  Azam Bozorgi; Maryam Bozorgi; Mozafar Khazaei
Journal:  Cell Oncol (Dordr)       Date:  2022-08-09       Impact factor: 7.051

2.  γδ T Cell-Based Adoptive Cell Therapies Against Solid Epithelial Tumors.

Authors:  Xiomar Bustos; Sebastian Snedal; Leticia Tordesillas; Eleonora Pelle; Daniel Abate-Daga
Journal:  Cancer J       Date:  2022 Jul-Aug 01       Impact factor: 2.074

3.  γ9δ2T cell diversity and the receptor interface with tumor cells.

Authors:  Anna Vyborova; Dennis X Beringer; Domenico Fasci; Froso Karaiskaki; Eline van Diest; Lovro Kramer; Aram de Haas; Jasper Sanders; Anke Janssen; Trudy Straetemans; Daniel Olive; Jeanette Leusen; Lola Boutin; Steven Nedellec; Samantha L Schwartz; Michael J Wester; Keith A Lidke; Emmanuel Scotet; Diane S Lidke; Albert Jr Heck; Zsolt Sebestyen; Jürgen Kuball
Journal:  J Clin Invest       Date:  2020-09-01       Impact factor: 14.808

4.  Aberrantly Expressed Embryonic Protein NODAL Alters Breast Cancer Cell Susceptibility to γδ T Cell Cytotoxicity.

Authors:  Gabrielle M Siegers; Indrani Dutta; Eun Young Kang; Jing Huang; Martin Köbel; Lynne-Marie Postovit
Journal:  Front Immunol       Date:  2020-06-19       Impact factor: 7.561

Review 5.  γδ T Cells: The Ideal Tool for Cancer Immunotherapy.

Authors:  Mahboubeh Yazdanifar; Giulia Barbarito; Alice Bertaina; Irma Airoldi
Journal:  Cells       Date:  2020-05-24       Impact factor: 6.600

Review 6.  T-Cell Gene Therapy in Cancer Immunotherapy: Why It Is No Longer Just CARs on The Road.

Authors:  Michael D Crowther; Inge Marie Svane; Özcan Met
Journal:  Cells       Date:  2020-06-30       Impact factor: 6.600

Review 7.  Engineering the Bridge between Innate and Adaptive Immunity for Cancer Immunotherapy: Focus on γδ T and NK Cells.

Authors:  Fabio Morandi; Mahboubeh Yazdanifar; Claudia Cocco; Alice Bertaina; Irma Airoldi
Journal:  Cells       Date:  2020-07-22       Impact factor: 6.600

Review 8.  CAR-T cells: Early successes in blood cancer and challenges in solid tumors.

Authors:  Hassan Dana; Ghanbar Mahmoodi Chalbatani; Seyed Amir Jalali; Hamid Reza Mirzaei; Stephan A Grupp; Eloah Rabello Suarez; Catarina Rapôso; Thomas J Webster
Journal:  Acta Pharm Sin B       Date:  2020-11-02       Impact factor: 11.413

Review 9.  The molecular basis of mammary gland development and epithelial differentiation.

Authors:  Priscila Ferreira Slepicka; Amritha Varshini Hanasoge Somasundara; Camila O Dos Santos
Journal:  Semin Cell Dev Biol       Date:  2020-10-17       Impact factor: 7.499

10.  Bibliometrics Analysis of Butyrophilins as Immune Regulators [1992-2019] and Implications for Cancer Prognosis.

Authors:  Yixi Wang; Na Zhao; Xianwen Zhang; Zhenhua Li; Zheng Liang; Jinrong Yang; Xingyu Liu; Yangzhe Wu; Kebing Chen; Yunfei Gao; Zhinan Yin; Xuejia Lin; Haibo Zhou; Dongbo Tian; Yang Cao; Jianlei Hao
Journal:  Front Immunol       Date:  2020-06-30       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.